Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02927340
Recruitment Status : Recruiting
First Posted : October 7, 2016
Last Update Posted : March 9, 2021
Sponsor:
Information provided by (Responsible Party):
Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : May 2023